The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

Background Numerous studies demonstrate associations between serum concentrations of
25-hydroxyvitamin D (25 [OH] D) and a variety of common disorders, including …

Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract …

Background Seasonal epidemics of respiratory syncytial virus (RSV) cause a clinically
significant burden of disease among young children. Non-pharmaceutical interventions …

Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants …

Background Vaccination against respiratory syncytial virus (RSV) during pregnancy may
protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F …

Background Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants.
The burden of RSV infection in healthy term infants has not yet been established. Accurate …

Background Early-life severe respiratory syncytial virus (RSV) infection has been associated
with the onset of childhood wheezing illnesses. However, the relationship between RSV …

Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion
conformation of the respiratory syncytial virus (RSV) F protein, which has been studied in …